Entera Bio Ltd (ENTX) Stock Price, Quote & News

Company Profile

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis;...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 2 532 7151

Website: www.enterabio.com

Address:

Kiryat Hadassah Minrav Building, Fifth Floor, Jerusalem, Israel

OneandOnly001 Apr. 17 at 7:46 PM

live setup firing. $ENTX cleared the trigger. here's the plan ↓ $ENTX (NASDAQ) $1.30 +8.3% 🔥44%SI 🟢 BUY NOW · Score 92/100 · Pre-Parabolic 📊 TRADE PLAN Entry: $1.32 Stop: $1.27 (3.7% risk) Target: $1.47 (+11.1% upside) R:R: 3.0:1 ✅ Vol +1078% · Above VWAP ✓ · Float 32M • MID move — holding above VWAP ($1.285), 1.1% extension — buyers in control • Volume 11.4× avg (+1078%) with steady 8.3% gain — strong accumulation pattern • Entry $1.321 → target $1.468, stop $1.272 — 3:1 R:R (3.7% risk) 🚀 EXPLOSIVE MOVERS (high risk · scalp only · NOT the buy pick): $ABLV +40.6% @ $0.816 🔥36%SI $AGAE +36.9% @ $0.714 $ABTS +34.5% @ $1.60 this is the exact plan i'm trading. risk tight under stop, scale into the target. 👇 the scanner caught this in real-time. free 3-day trial, no card: https://micro-stock-scout.replit.app #smallcaps #daytrading #scalping #vwap

0 · Reply

OneandOnly001 Apr. 17 at 7:17 PM

scanner stats this session: 1 VWAP-confirmed BUYs, 169 qualifying movers. most recent BUYs: $ENTX +8.7% @ $1.30 🔥44%SI the scanner is doing the work. i just watch the alerts. hit it up if you want the live feed 👉 https://micro-stock-scout.replit.app #daytrader #stockmarket #scalping #daytrading #pennystocks

0 · Reply

TradeForLifeKing Apr. 17 at 6:20 PM

$UCAR only 2MIL float stock and uptrending, this how epic runs happen, just saying, we may see this skyrocket to dobule digits any day now.... $SMX $AMC $DVLT $ENTX

0 · Reply

OneandOnly001 Apr. 17 at 6:18 PM

🚨 LIVE TRADE PLAN — $ENTX just triggered BUY on the scanner: $ENTX (NASDAQ) $1.29 +7.9% 🔥44%SI 🟢 BUY NOW · Score 97/100 · Pre-Parabolic 📊 TRADE PLAN Entry: $1.31 Stop: $1.27 (3.1% risk) Target: $1.43 (+9.3% upside) R:R: 3.0:1 ✅ Vol +1415% · Above VWAP ✓ · Float 32M • EARLY — cleanly above VWAP ($1.284), tight hold near breakout level — ideal entry zone • Volume 11.1× avg (+1415%) with steady 7.9% gain — strong accumulation pattern • Entry $1.311 → target $1.433, stop $1.271 — 3:1 R:R (3.1% risk) 🚀 EXPLOSIVE MOVERS (high risk · scalp only · NOT the buy pick): $ABLV +31.0% @ $0.760 🔥36%SI $UCAR +28.7% @ $1.48 🔥28%SI $IFRX +27.9% @ $1.53 this is the exact plan i'm trading. risk tight under stop, scale into the target. 👇 the scanner caught this in real-time. free 3-day trial, no card: https://micro-stock-scout.replit.app #daytrader #daytrading #momentum #breakouts #vwap

0 · Reply

OneandOnly001 Apr. 17 at 5:30 PM

live setup firing. $ENTX cleared the trigger. here's the plan ↓ $ENTX (NASDAQ) $1.27 +6.2% 🔥44%SI 🟢 BUY NOW · Score 89/100 · Early Build 📊 TRADE PLAN Entry: $1.31 Stop: $1.26 (4.2% risk) Target: $1.48 (+12.6% upside) R:R: 3.0:1 ✅ Vol +1699% · Above VWAP ✓ · Float 32M • EARLY — cleanly above VWAP ($1.269), tight hold near breakout level — ideal entry zone • Volume 11.0× avg (+1699%) with steady 6.2% gain — strong accumulation pattern • Entry $1.311 → target $1.476, stop $1.256 — 3:1 R:R (4.2% risk) 🚀 EXPLOSIVE MOVERS (high risk · scalp only · NOT the buy pick): $IFRX +30.3% @ $1.57 $UCAR +26.1% @ $1.45 🔥28%SI $ABLV +25.0% @ $0.725 🔥36%SI scanner's job is to find these. mine is to execute the plan and not babysit. 👇 the scanner caught this in real-time. free 3-day trial, no card: https://micro-stock-scout.replit.app #scalping #momentum #smallcaps

0 · Reply

RenaissanceTrading Apr. 17 at 2:42 PM

$ENTX Over $1.29 should see $1.56+

0 · Reply

TheGodsMustBeCrazy Apr. 17 at 2:15 PM

$ENTX Does someone know something? Someone bought over 1M shares today pre market. Huge volume spike.

0 · Reply

liloleme4 Apr. 17 at 1:24 PM

$ENTX Came here to check myself after not seeing anything seemingly important elsewhere. With the price spiking to $1.84 at the time, someone big had to want to buy in badly - enough not to care about share price, even for that many shares

0 · Reply

Tomakak Apr. 17 at 11:44 AM

$ENTX 1.4mil shares float pre, whats happening?

0 · Reply

Libor_the_Bull Apr. 17 at 9:31 AM

$ENTX wow

0 · Reply

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613

Apr 6, 2026, 1:50 PM EDT - 11 days ago

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

Apr 2, 2026, 8:45 AM EDT - 15 days ago

Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

Mar 27, 2026, 4:05 PM EDT - 21 days ago

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

Mar 4, 2026, 8:30 AM EST - 6 weeks ago

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Feb 11, 2026, 9:00 AM EST - 2 months ago

Entera Bio Announces Open Market Purchases of Company Stock by Board Members

Feb 9, 2026, 8:50 AM EST - 2 months ago

Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones

Dec 23, 2025, 8:30 AM EST - 4 months ago

Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation

Dec 22, 2025, 8:30 AM EST - 4 months ago

Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)

Nov 18, 2025, 8:00 AM EST - 5 months ago

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

Oct 23, 2025, 8:50 AM EDT - 6 months ago

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

Oct 16, 2025, 8:45 AM EDT - 6 months ago

Entera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual Meeting

Aug 8, 2025, 4:05 PM EDT - 9 months ago

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Jul 28, 2025, 7:30 AM EDT - 9 months ago

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

May 9, 2025, 4:05 PM EDT - 1 year ago

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

Mar 28, 2025, 4:05 PM EDT - 1 year ago

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

Mar 17, 2025, 8:00 AM EDT - 1 year ago

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Feb 24, 2025, 8:30 AM EST - 1 year ago

Entera Bio to Participate in Upcoming Events

Jan 27, 2025, 8:00 AM EST - 1 year ago

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Nov 8, 2024, 4:05 PM EST - 1 year ago

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Aug 9, 2024, 4:05 PM EDT - 1 year ago

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

May 15, 2024, 8:00 AM EDT - 2 years ago

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

May 13, 2024, 7:00 AM EDT - 2 years ago

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

May 10, 2024, 4:10 PM EDT - 2 years ago

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Mar 26, 2024, 8:30 AM EDT - 2 years ago

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Mar 20, 2024, 8:00 AM EDT - 2 years ago

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Mar 8, 2024, 4:05 PM EST - 2 years ago

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Mar 4, 2024, 8:30 AM EST - 2 years ago

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jan 30, 2024, 8:30 AM EST - 2 years ago

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 3, 2024, 8:00 AM EST - 2 years ago

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Dec 26, 2023, 8:00 AM EST - 2 years ago

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Nov 29, 2023, 8:30 AM EST - 2 years ago

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Nov 14, 2023, 7:30 AM EST - 2 years ago

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Nov 9, 2023, 2:30 PM EST - 2 years ago

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

Sep 12, 2023, 8:30 AM EDT - 2 years ago

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Entera Bio to Participate in Upcoming Investor Conferences

Aug 16, 2023, 8:30 AM EDT - 2 years ago

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

Jun 7, 2023, 7:30 AM EDT - 3 years ago

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

May 5, 2023, 4:05 PM EDT - 3 years ago

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

May 3, 2023, 9:34 AM EDT - 3 years ago

Entera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

Apr 26, 2023, 8:30 AM EDT - 3 years ago

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Board

Apr 3, 2023, 7:00 AM EDT - 3 years ago

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

Mar 31, 2023, 4:00 PM EDT - 3 years ago

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

Mar 23, 2023, 9:27 AM EDT - 3 years ago

Entera Bio Regains Compliance with Nasdaq Listing Requirements

Feb 15, 2023, 10:00 AM EST - 3 years ago

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

OneandOnly001 Apr. 17 at 7:46 PM

0 · Reply

OneandOnly001 Apr. 17 at 7:17 PM

0 · Reply

TradeForLifeKing Apr. 17 at 6:20 PM

$UCAR only 2MIL float stock and uptrending, this how epic runs happen, just saying, we may see this skyrocket to dobule digits any day now.... $SMX $AMC $DVLT $ENTX

0 · Reply

OneandOnly001 Apr. 17 at 6:18 PM

0 · Reply

OneandOnly001 Apr. 17 at 5:30 PM

0 · Reply

RenaissanceTrading Apr. 17 at 2:42 PM

$ENTX Over $1.29 should see $1.56+

0 · Reply

TheGodsMustBeCrazy Apr. 17 at 2:15 PM

$ENTX Does someone know something? Someone bought over 1M shares today pre market. Huge volume spike.

0 · Reply

liloleme4 Apr. 17 at 1:24 PM

0 · Reply

Tomakak Apr. 17 at 11:44 AM

$ENTX 1.4mil shares float pre, whats happening?

0 · Reply

Libor_the_Bull Apr. 17 at 9:31 AM

$ENTX wow

0 · Reply

IRTeam Apr. 14 at 1:15 PM

$ENTX Entera Bio to host a key opinion leader virtual webinar on Monday, April 20, 2026 at 11:00 AM Eastern Time. Topic: The Osteoporosis Treatment Landscape and the Clinical Perspective on Entera’s Lead Clinical Candidate, EB613 Registration: https://events.zoom.us/ev/AjJwNRe2lJ20ip76GJ4k0Ee_SLHBTKEcb9Iabu7PDwVyGRBCzqr_~AqIJON0d6_lhurfYvEmThe3o4X3G0iFAy9zFmuBnQMCqifflBtC23k66Fg More info in the press release: https://www.globenewswire.com/news-release/2026/04/14/3273411/0/en/Entera-Bio-to-Host-Key-Opinion-Leader-Webinar-Highlighting-the-Osteoporosis-Treatment-Landscape-and-the-Opportunity-for-EB613.html

0 · Reply

WallStWireAds Apr. 14 at 12:47 PM

$ENTX https://www.globenewswire.com/news-release/2026/04/14/3273411/0/en/Entera-Bio-to-Host-Key-Opinion-Leader-Webinar-Highlighting-the-Ost

0 · Reply

chunkynuts Apr. 10 at 2:08 PM

$ENTX 0 volume ? Wtf

0 · Reply

WallStWireAds Apr. 9 at 11:40 AM

$ENTX New Cap Notes Report: Bones of a Bet: Why the Smart Money That Backed ChemoCentryx, Blueprint and Protagonist Just Put Its Chips on Entera Bio https://capnotes.beehiiv.com/p/bones-of-a-bet-why-the-smart-money-that-backed-chemocentryx-blueprint-and-protagonist-just-put-its-c The fund that backed ChemoCentryx ($3.7B exit), Blueprint Medicines ($9.1B exit) and Protagonist Therapeutics ($5.9B+ valuation) just invested in Entera Bio – a $54 million company developing the world’s first oral bone-building pill, with Phase 3 on the launchpad and an FDA response due in weeks. $CCXI $BPMC $PTGX $VKTX

0 · Reply

RunningRobert1 Apr. 2 at 3:02 PM

$ENTX Ok even with the cash raise, do they have enough money to get to data in 2H 2028?

0 · Reply

WallStWireAds Apr. 2 at 1:56 PM

$ENTX https://www.globenewswire.com/news-release/2026/04/02/3267368/0/en/Entera-Bio-Announces-Pricing-of-10-0-Million-Direct-Investment-by-

0 · Reply

Stock_Catcher Apr. 2 at 1:45 PM

$ENTX Riding the 9 EMA

0 · Reply

Ive_Got_Options Apr. 2 at 1:40 PM

$ENTX She thought I was only 4 inches

0 · Reply

Ive_Got_Options Apr. 2 at 12:54 PM

$ENTX lol nothing has as good of news as $ELAB or $CYCN had

0 · Reply

Ive_Got_Options Apr. 2 at 12:48 PM

$ENTX Bigger than 9% tell you that much...

0 · Reply

Stock_Catcher Apr. 2 at 12:45 PM

$ENTX Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds

0 · Reply

StoneGlare Mar. 31 at 10:59 PM

$ENTX and $TGHL going to be multi day runners

0 · Reply

Market Cap	55.01M
Revenue (ttm)	40,000.00
Net Income (ttm)	-11.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28,600.00%
Debt to Equity Ratio	0.00

Volume	1,944,302
Avg Vol	170,780
Day's Range	N/A - N/A
Shares Out	46.62M
Stochastic %K	56%
Beta	1.54
Analysts	Sell
Price Target	$10.00